Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.
Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter F
| Generic Name | Trade Name | Condition | Study Code | Study Name | Access to study | Access to results |
|---|---|---|---|---|---|---|
| FATTY ACID AMIDE HYDROLASE INHIBITOR | Not marketed | Cancer pain | ACT11705 | NA | EudraCT: 2011-002557-56 | |
| FATTY ACID AMIDE HYDROLASE INHIBITOR | Not marketed | Major Depressive Disorder | DFI10560 | FIDELIO | EudraCT: 2008-001718-26 | |
| FEDRATINIB | Not marketed | Myelofibrosis | ARD12888 | NA | NCT01692366 | |
| FEDRATINIB | Not marketed | Myelofibrosis | ARD12888 | NA | NCT01692366 | |
| FEDRATINIB | Not marketed | Hematopoietic Neoplasm | ARD12042 | NA | NCT01420783 | |
| FEDRATINIB | Not marketed | Hematopoietic Neoplasm | ARD11936 | NA | NCT01420770 | |
| FEDRATINIB | Not marketed | Neoplasm malignant | TES13519 | NA | NCT01836705 | |
| FEDRATINIB | Not marketed | Hematopoietic Neoplasm | ARD12181 | JAKARTA2 | NCT01523171 | |
| FEDRATINIB | Not marketed | Myelofibrosis | EFC12153 | JAKARTA | EudraCT: 2011-001897-25 | |
| FEDRATINIB | Not marketed | Solid Tumor | INT12497 | NA | NCT01585623 | |
| FEDRATINIB | Not marketed | Renal Impairment | POP13449 | NA | NCT01763190 | |
| FEDRATINIB | Not marketed | Hepatic Impairment | POP13450 | NA | NCT01762462 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Urticaria | M016455_4001 | NA | NA | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Urticaria | M016455A_4121 | NA | NA | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Rhinitis, Seasonal | M016455_4124 | NA | NCT00636870 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Cognition | M016455A_4139 | NA | NCT00637455 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Urticaria | M016455A_4143 | NA | NA | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Urticaria | M016455A_4144 | NA | NCT00547768 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Seasonal allergy | M016455A_4145 | NA | NCT00637585 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Seasonal allergy | M016455A_4146 | NA | NCT00638118 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Cat allergy symptoms | M016455A_4148 | NA | NCT00637884 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Seasonal Allergic Rhinitis | M016455A_4149 | NA | NCT00637611 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Seasonal Allergic Rhinitis | M016455C_4001 | NA | NCT00741897 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Rhinitis Perennial | SFY10717 | NA | NCT01244217 | |
| FEXOFENADINE HYDROCHLORIDE | Allegra | Atopic Dermatitis | SFY10718 | NA | NCT01244230 | |
| FEXOFENADINE HCl - PSEUDOEPHEDRINE HCl combination | Allegra-D | Rhinitis Perennial | EFC11243 | NA | NCT01306721 | |
| FEXOFENADINE HCl - PSEUDOEPHEDRINE HCl combination | Allegra-D | Allergic Rhinitis | FEXHYL06934 | NA | NCT02175485 | |
| FLUOROURACIL | Carac | Keratosis | DL6025-0201 | NA | NCT00377273 | |
| FRESOLIMUMAB | Glomerulosclerosis | GC1008FSGS03110 | NA | EudraCT: 2012-002365-35 | ||
| FUROSEMIDE | Lasix, Eutensin, Lasilix | Chronic Renal Failure | FUROSL06121 | NA | NCT01724788 |
References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted